Primary source: Standard CTDA pathway: process for desktop review
The introduction of a CTDA renewal process requiring manufacturers to apply for renewal through a new digital portal, starting from 13 August 2026.
This change enhances ongoing oversight and compliance by mandating periodic re-validation of tests, thus ensuring continued safety and efficacy in the market amid evolving standards.
Manufacturers must submit renewal applications for CTDA certificates with a £420 fee (discounted to £168 for small organizations) and respond to any requests for additional information within 20 working days.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Introduction of a formal renewal cycle for COVID-19 test approvals; launch of a new digital portal for renewal applications; updated documentation requirements for demonstrating ongoing compliance and safety.
The new renewal process enhances post-market oversight by requiring periodic re-validation of approved test devices. This systematic approach ensures the ongoing monitoring of safety and performance, requiring manufacturers to maintain robust vigilance data to support renewal applications.
Manufacturers must prepare for a streamlined renewal process to ensure continued market access.
Introduction of the CTDA Renewal Process.
Manufacturers must submit renewal applications for CTDA certificates with a £420 fee (discounted to £168 for small organizations) and respond to any requests for additional information within 20 working days.
The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented a structured renewal process for the Coronavirus Test Device Approvals (CTDA). This includes a new digital portal for applications, updated compliance documentation requirements, and a formal re-validation cycle to enhance post-market oversight and safety monitoring of COVID-19 diagnostic tests.
What changed: The introduction of a CTDA renewal process requiring manufacturers to apply for renewal through a new digital portal, starting from 13 August 2026.
Why it matters: This change enhances ongoing oversight and compliance by mandating periodic re-validation of tests, thus ensuring continued safety and efficacy in the market amid evolving standards.
Practical implication: Manufacturers must submit renewal applications for CTDA certificates with a £420 fee (discounted to £168 for small organizations) and respond to any requests for additional information within 20 working days.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
